Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
10.1200/jco.2008.20.1293 · 2009
Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
10.1200/jco.2008.19.5511 · 2009
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
10.1200/jco.2009.23.9764 · 2010
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
10.1016/s0140-6736(11)61613-9 · 2011
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
10.1148/radiol.2521081059 · 2009
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
10.1158/1535-7163.mct-10-0477 · 2010
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
10.1158/0008-5472.can-09-3965 · 2010
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
10.1016/j.ccr.2005.09.005 · 2005
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody
10.1158/1535-7163.mct-10-0213 · 2010
Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth
10.1158/1078-0432.ccr-10-2317 · 2011
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors
10.1200/jco.2008.19.6683 · 2009
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
10.1200/jco.2010.34.3178 · 2012
Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels
10.2353/ajpath.2009.090391 · 2009
Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy
10.1158/0008-5472.can-12-4697 · 2013
Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth
10.1158/0008-5472.can-09-1977 · 2010
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models
10.1158/1535-7163.mct-09-0554 · 2010
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
10.1371/journal.pone.0019144 · 2011
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
10.1038/bjc.2012.591 · 2013
Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow
10.1097/00004647-199611000-00019 · 1996
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition
10.1158/0008-5472.can-12-2064 · 2013
Modes of resistance to anti-angiogenic therapy
10.1038/nrc2442 · 2008
Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors
10.1593/tlo.10136 · 2010
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
10.1038/bjc.2012.594 · 2013
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
10.1093/annonc/mds502 · 2013
Unresolved referenced work
Kept as external metadata until matched
